Soluble Platelet Glycoprotein V in Distinct Disease States of Pathological Thrombopoiesis

Department of Hematology, Selcuk University Meram Medical School, Konya, Turkey.
Journal of the National Medical Association (Impact Factor: 0.96). 02/2008; 100(1):86-90. DOI: 10.1016/S0027-9684(15)31180-9
Source: PubMed


Quantitative platelet disorders (i.e., thrombocytosis or thrombocytopenia) may also be associated with qualitative platelet alterations. Clonal thrombocythemia (CT), reactive thrombocytosis (RT), immune thrombocytopenic purpura (ITP), and thrombocytopenia of aplastic pancytopenia (AA) or infiltrative bone marrow disorders represent the major classes of pathological thrombopoiesis. Glycoprotein V may serve as an in vivo marker of platelet activation in thrombotic and hemorrhagic states. The aim of this study was to assess circulating plasma soluble platelet glycoprotein V (sGPV) concentrations in distinct disease states of pathological thrombopoiesis. The whole study group comprised 20 patients with thrombocytopenia, 32 patients with thrombocytosis and 14 healthy adults as the control group. sGPV was significantly increased in the group of thrombocytosis patients in comparison to the thrombocytopenic group and the healthy control groups. When sGPV levels were corrected according to platelet number (sGPV/tr), this ratio was very high in patients with thrombocytopenia compared to patients with thrombocytosis and the control group. Our results suggest that there is an ongoing platelet activation associated with thrombocytosis regardless of its origin is either CT or RT. Therefore, glycoprotein V system may serve to activate residual platelets in thrombocytopenia regardless of its origin is either ITP or AA.

Download full-text


Available from: Salih Aksu
  • [Show abstract] [Hide abstract]
    ABSTRACT: Identifying the genes that cause disease is one of the most challenging issues to establish the diagnosis and treatment quickly. Several interesting methods have been introduced for disease gene identification for a decade. In general, the main differences between these methods are the type of data used as a prior-knowledge, as well as machine learning (ML) methods used for identification. The disease gene identification task has been commonly viewed by ML methods as a binary classification problem (whether any gene is disease or not). However, the nature of the data (since there is no negative data available for training or leaners) creates a major problem which affect the results. In this paper, sequence-based, one class classification method is introduced to assign genes to disease class (yes, no). First, to generate feature vector, the sequences of proteins (genes) are initially transformed to numerical vector using physicochemical properties of amino acid. Second, as there is no definite approach to define non-disease genes (negative data); we have attempted to model solely disease genes (positive data) to make a prediction by employing Support Vector Data Description algorithm. The experimental results confirm the efficiency of the method with precision, recall and F-measure of 79.3%, 82.6% and 80.9, respectively. Copyright © 2015. Published by Elsevier Inc.
    No preview · Article · Jul 2015 · Journal of Biomedical Informatics